¶ÈÀÓ¾Ò²ð

2009ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamahita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A ; Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.
    Am J Med Genet B Neuropsychiatr Genet ; 150B(1)115-123
  2. Kato M, Okugawa G, Wakeno M, Takekita Y, Nonen S, Tetsuo S, Nishida K, Azuma J, Kinoshita T, Serretti A ; Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European neuropsychopharmacology19(10)718-25
  3. Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serritti A ; 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients ; Psychiatric Research167(1-2)97-105
  4. Kinoshita T ; Epigenetics in Psychiatry. Neuropsychobiology60(1)1
  5. Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, Shinosaki K, Yoneda H, Kishimoto T, Kinoshita T ; Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai psychiatric multicenter study. Psychiatry and clinical neurosciences 63(3)322-328
  6. Tsutsumi A, Kanazawa T, Kikuyama H, Okugawa G, Uenishi H, Miyamoto T, Matsumoto N, Koh J, Shinosaki K, Kishimoto T, Yoneda H, Kinoshita T ; Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone.Psychiatry Investigation 6(3)222-225
  7. Lawyer G, Nesvag R, Varnas K, Okugawa G, Aqartz I ; Grey and White Matter Propotional Relationships in the Cerebellar Vermis Altered in Schizophrenia.Cerebellum 8(1)52-60,2009
  8. Morishita S, Kinoshita T ; Gender differences in response to antidepressants.Current topics in pharmacology 13(2)51-64
  9. ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤Ë̸µ ·ò¡¤ Æþß· ÁÌÚ²¼Íøɧ ; ½éÏ·´ü¤Ë¤ß¤é¤ì¤ëÍÞ¤¦¤Ä¾É¾õ¤ËÂФ·¤Æ¥ê¥Á¥¦¥à¤¬ÁÕ¸ú¤·¤¿2¾ÉÎã.Bipolar disorder 7:13-19
  10. ÌÚ²¼Íøɧ ; ¿·µ¬¹³¤¦¤ÄÌômirtazapine¤Î¤¦¤ÄɵڤӤ¦¤Ä¾õÂ֤δµ¼Ô¤òÂоݤȤ·¤¿¥×¥é¥»¥ÜÂоÈÆó½ÅÌÕ¸¡Èæ³Ó»î¸³.Î×¾²Àº¿ÀÌôÍý12(2):289-306
  11. ÌÚ²¼Íøɧ ; ¿·µ¬¤¦¤ÄÌômirtazapine¤Î¤¦¤ÄɵڤӤ¦¤Ä¾õÂ֤δµ¼Ô¤òÂоݤȤ·¤¿Ä¹´üÅêÍ¿»î¸³.Î×¾²Àº¿ÀÌôÍý12(3):503-520
  12. À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë¡¤ µÈÅľ﹧¡¤Æþß·Á¿¹ÅļÓÀ顤°ëë½ÓÌÀ¡¤ ÌÚ²¼Íøɧ ; FTD(frontotemporal dementia)´µ¼Ô¤Î¼þÇÈ¿ô²òÀϤòÍѤ¤¤¿¸¦µæ.ÆüËÜÌôʪǾÇȳزñ»¨»ï10(1):63-66
  13. óîÆ£¹¬»Ò ; ¶¯Ç÷À­¾ã³²¤Ë¤ª¤±¤ë¿·¤·¤¤Ç¾²èÁü¸¦µæ(³È»¶¥Æ¥ó¥½¥ë²èÁü²òÀϤˤè¤ëÎ×¾²½Å¾ÉÅÙȽÄê¤Î²ÄǽÀ­¤Ë¤Ä¤¤¤Æ). ´ØÀ¾°å²ÊÂç³Ø»¨»ï61(2):212-21
  14. ÅĶᰡÍö¡¤°¤Éô¾°¡¤ºä°æ»ÖÈÁ¡¤ ʬÌîÀµµ®¡¤¾åÌîÀéÊ桤µÈ¼¶©»Ë¡¤ÌÚ²¼Íøɧ ; ¥¨¥È¥µ¥¯¥·¥ß¥É¤Ë¤è¤êǾÇȤζ¯À©Àµ¾ï²½¤òÍ褿¤·åÈÌÛ¾õÂÖ¤òÄ褷¤¿°ìÎã.Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï20(1)3-8
  15. ¾åÌîÀéÊ桤ÌÚ²¼Íøɧ¡¤ »³Ëܹ¬ÎÉ ; Àº¿À²Ê°å¤¬½Ð²ñ¤¦È¯Ã£¾ã³²¼Ô¤ÎÎ×¾²ÅªÌäÂêÅÀ¡½¤È¤¯¤Ë¹­ÈÆÀ­È¯Ã£¾ã³²¤òÃæ¿´¤Ë.ÆüËÜÀº¿À²Êɱ¡¶¨²ñ»¨»ï28(8)646-652
  16. µÈ¼¶©»Ë¡¤°ëë½ÓÌÀ¡¤Æþß· ÁÀ¾ÅÄ·½°ìϺ¡¤»³ÅÄ·½Â¤¡¤ ¿¹ÅļÓÀ顤 ÖÖË̲µ±¡¤Ë̱ºÍ´°ì¡¤¿Ûˬ°´¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ¹³Àº¿ÀÉÂÌôñ²óÅêÍ¿¤¬·ò¾ï¼Ô¤ÎǾÅžì¤ËµÚ¤Ü¤¹±Æ¶Á Êñ³çŪ»Øɸ¤òÍѤ¤¤Æ.ÆüËÜÌôʪǾÇȳزñ»¨»ï 10(1)43-48
  17. µÈ¼¶©»Ë¡¤ã·Æ£¹¬»Ò¡¤±ä¸¶·òÆó¡¤ °ëë½ÓÌÀ¡¤µÆÃÓ ½¼¡¤ ±üÀî ³Ø¡¤Æþß· ÁÀ¾ÅÄ·½°ìϺ¡¤¿¹ÅļÓÀ顤Ë̱ºÍ´°ì¡¤Koenig Thomas¡¤ÌÚ²¼Íøɧ ; ǾÇÈ¡¦¶ÚÅÅ¿Þ¤ÎÎ×¾² ¶¯Ç÷À­¾ã³²¤Î¶õ´ÖŪǾµ¡Ç½¸¦µæ ¾É¾õͶȯ¤Ë¤è¤ëÊѲ½.Î×¾²Ç¾ÇÈ51(9)560-567
  18. À¾Â¼±ÉÄŻҡ¤ »°°æ¹À¡¤Ã«Ëü´î»Ò¡¤¹âÅĤ¢¤ä¡¤ÎëÌÚ½ÓÌÀ¡¤ÌÚ²¼Íøɧ¡¤ÌøÀ¸Î´»ë ; ÁжËÀ­¾ã³²¤Î²ÃÎÅÃæ¤ËÀ¸¤¸¤¿ÃÙȯÀ­¥¸¥¹¥È¥Ë¥¢¤ËÂФ¹¤ë謁£ÎÅ.´ØÀ¾°åÎÅÂç³ØµªÍ×3:115-120
  19. ¾åÅľȻҡ¤»°Âð¿¿Íý¡¤À¾»³ÍøÀµ¡¤ÅĶᰡÍö¡¤ ¹Ó°æͳÈþ»Ò ; Íײð¸î¹âÎð¼Ô¤Î©»Ò¤Ë¤è¤ëµÔÂÔ¤ÎÍ×°ø¤È¿ȯ¤ÎÇØ·Ê¡¥¸üÀ¸¤Î»Øɸ55(6):19-26
  20. »°ÂðâÃÍý¡¤Anne Rock¡¤ÅĶᰡÍö¡¤ÊÝÄÅ¿¿°ìϺ¡¤¿ÎÌÚÌ­¡¤Ê¿ÌÚ¹¨»ù¡¤ À¾»³ÍøÀµ ; ¥ª¡¼¥¹¥È¥é¥ê¥¢¤ÈÆüËܤιâÎð¼Ô²ð¸î»ÜÀߤˤª¤±¤ë¥±¥¢¤Ë¤Ä¤¤¤Æ¤Î¸¦µæ.¥ª¡¼¥¹¥È¥é¥ê¥¢¸¦µæ22:73-75

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ²ÃÆ£Àµ¼ù¡¤ Ê¡ÅĹä»Ë¡¤Ê¬ÌîÀµµ®¡¤±üÀî ³Ø¡¤ ÖÖË̲µ±¡¤Alessandro Serretti, Åì ½ã°ì¡¤ ÌÚ²¼Íøɧ ; Â礦¤ÄÉÂÀ­¾ã³²´µ¼Ô¤Ë¤ª¤±¤ë¹³¤¦¤ÄÌô¤Î¼£ÎÅÈ¿±þ¤ËÂФ¹¤ë5-HT1A¼õÍÆÂΰäÅÁ»Ò¿·¿¤Î±Æ¶Á.ÆüËÜ¿À·ÐÀº¿ÀÌôÍý³Ø»¨»ï29:23-31
  2. ²ÃÆ£Àµ¼ù¡¤±üÀî ³Ø¡¤ÌÚ²¼Íøɧ ; ¡Ú¿·µ¬¹³¤Æ¤ó¤«¤óÌôlamotrigine ¡Ûµ¤Ê¬°ÂÄêÌô¤È¤·¤Æ¤Îlamotrigine¡½ÁжËÀ­¾ã³²¼£ÎŤˤª¤±¤ëÍ­¸úÀ­¡½.Î×¾²Àº¿ÀÌôÍý12(5)903-912
  3. ²ÃÆ£Àµ¼ù ; ¥Õ¥¡¡¼¥Þ¥³¥²¥Î¥ß¥¯¥¹-¸ÄÊ̲½°åÎŤÈÌôºÞ´¶¼õÀ­ Àº¿À²ÊÎΰè¤Î¸ÄÊ̲½°åÎŤθ½¾õ¤Èº£¸å¡¥°å³Ø¤Î¤¢¤æ¤ß230(6Ž¥7)458-462
  4. ²ÃÆ£Àµ¼ù ; Î×¾²ÌôÍý³Ø³¤³°¸¦½¤¤ò½ª¤¨¤Æ.À½Ìô¶¨¥Ë¥å¡¼¥º¥ì¥¿¡¼132:36-40
  5. ²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; ¡ÚÆý¸ ¹³¤Æ¤ó¤«¤óÌô¡Û¾­Íè¡¢¤É¤ó¤Ê¤Æ¤ó¤«¤ó¼£ÎŤ¬´üÂÔ¤µ¤ì¤ë¤« ¡Ýpharmacogenetics¤È¸ÄÊ̲½¼£ÎŤβÄǽÀ­¡Ý.ºÇ¿·Àº¿À°å³Ø14(4)361-368
  6. ÌÚ²¼Íøɧ ; Blonanserin¤Î´ðÁäÈÎ×¾².Î×¾²Àº¿ÀÌôÍý12(3)547-555
  7. ±üÀî ³Ø¡¤¹âÀ¥¾¡¶µ¡¤óîÆ£¹¬»Ò¡¤ÌÚ²¼Íøɧ ; MRI-¤ª¤µ¤¨¤Æ¤ª¤­¤¿¤¤¥Ý¥¤¥ó¥È ³È»¶¥Æ¥ó¥½¥ë²èÁü.Àº¿À²Ê 14(4)312-315
  8. ÖÖË̲µ± ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëperospirone¤Èaripiprazole¤Î̵ºî°Ù³äÉÕÈæ³Ó»î¸³¡Á»ÈÍѤÎŬÀµ²½¤òÌܻؤ·¤Æ¡Á.Î×¾²Àº¿ÀÌôÍý12(12):2630-2633
  9. ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; SSRI¤ÎŬ±þ¤Î³ÈÂç¤Èº£¸å¤ÎŸ˾.Î×¾²¤È¸¦µæ86(8)949-953
  10. µÈ¼¶©»Ë¡¤ ¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ¡¤ À¾ÅÄ·½°ìϺ¡¤ÅĶᰡÍö¡¤ ÖÖË̲µ±¡¤ ÎëÌÚÈþº´¡¤ÌÚ²¼Íøɧ ; ǧÃξɰåÎŤˤª¤¤¤ÆÁí¹çɱ¡Àº¿À²ÊÉÂÅ郎²Ì¤¿¤¹Ìò³ä. Áí¹çɱ¡Àº¿À°å³Ø21(3)243-250
  11. ÎëÌÚÊþ»Ò¡¤²¬Â¼¹¨Èþ¡¤ÌÚ²¼Íøɧ ; »°ÅÄë·¼¤Ë¤è¤ë¥Ó¥Í¼°ÃÎǽ¸¡ºº¤Î²þÄû. ¿´Íý³Ø»Ë¡¦¿´Íý³ØÏÀ10-11:1-10

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ÌÚ²¼Íøɧ¡¤À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë ; ­µ¿ÇÃǤò¤Ä¤±¤ë¤¿¤á¤Ë F.¸¡ºº 1.¿À·ÐÀ¸Íý¸¡ºº. Àº¿À²ÊÀìÌç°å¤Î¤¿¤á¤Î¥×¥é¥¯¥Æ¥£¥«¥ëÀº¿À°å³Ø ; 177-186 Ã滳½ÐÈÇ
  2. Nishida K, Yoshimura M, Suwa A, Kitaura Y, Kono S, Isotani T, Kinoshita T ; A Case Report:The Change of EEG Findings in General Paresis before and after Penicillin-G Treatment.Brain Topography and multimodal imaging ; 253-255µþÅÔÂç³Ø³Ø½Ñ½ÐÈÇ
  3. ¿ùËÜãºÈ ; ¤¦¤ÄÌôÃæÆÇ(»°´Ä·Ï¡¢»Í´Ä·Ï)¡¢Ãº»À¥ê¥Á¥¦¥àÃæÆÇ.º£Æü¤Î¼£ÎÅ»Ø¿Ë 2009ǯÈÇ(Vol.51) ; 115-116 °å³Ø½ñ±¡

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2008ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y,Takekita Y, Mandelli L, Azuma J, Kinoshita T ; ABCB1MDR1gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.Prog Neuropsychopharmacol Biol Psychiatry 32(2)398-404
  2. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamahita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A ; Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.
    Am J Med Genet B Neuropsychiatr Genet.150B(1)115-123
  3. Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A2008Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Prog Neuropsychopharmacol Biol Psychiatry32(4)1041-1044
  4. Morishita S, Kinoshita T ; Predictors of response to sertraline in patients
    with major depression. Hum.Psychopharmacol Clin Exp 23:647-651
  5. Saito Y, Nobuhara K, Okugawa G, Takase K, Sugimoto T, Horiuchi M, Ueno C, Maehara M, Omura N, Kurokawa H, Ikeda K, Tanigawa N, Sawada S, Kinoshita T ; Corpus Callosum in Patients with Obsessive-Compulsive Disorder: Diffusion-Tensor Imaging Study. Radiology246(2)536-542.
  6. Serretti A, Kato M ; The serotonin transporter gene and effectiveness of SSRIs.
    Expert Rev Neurother 8(1111-120
  7. Serretti A, Kato M, Kennedy JL ; Pharmacogenetic studies in depression: a proposal for methodologic guidelines.Pharmacogenomics J 8(2)90-100
  8. Sugimoto T, Tanigawa N, Ikeda K, Ohmura N, Maehara M, Kariya S, Kojima H, Komemushi A, Ha-Kawa SK, Saito.Y, Tajika A, Kinoshita T, Sawada S ; Diffusion-Weighted Imaging for Predicting New Compression Fractures Following Percutaneous Vertebroplasty. Acta Radiologica 49(4)419-426.
  9. Tani M, Suzuki T, Takada A, Yagyu T, Kinoshita T ; The acupuncture treatment of severe
    axial dystonia The Journal of Chinese Medicine 87: 5-8
  10. Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, Yamashita M, Nonen S, Azuma J, Kinoshita T ; The Alpha 2A-Adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 28(5)518-524
  11. ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤Ë̸µ ·ò¡¤»³ÅÄ·½Â¤¡¤ÌÚ²¼Íøɧ ; ÁжËÀ­À®Ê¬¤ËÃíÌܤ¹¤ë¤³¤È¤Ë¤è¤êÁжËÀ­¾ã³²¤Ë¿ÇÃǤòÊѹ¹¤·²þÁ±¤¬¤ß¤é¤ì¤¿µ¤Ê¬¾ã³²¤Î12Îã¤Ë¤Ä¤¤¤Æ¤Î¹Í»¡¡¥Bipolar Disorder 6: 32-36
  12. ÌÚ²¼Íøɧ ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëblonanserin¤ÎĹ´üÅêÍ¿»î¸³ ¿»ÜÀ߶¦Æ±¥ª¡¼¥×¥ó»î¸³¡¥Î×¾²Àº¿ÀÌôÍý11(1)135-153
  13. ¿¹ÅļÓÀ顤¾åÌîÀéÊ桤¹âÀ¥¾¡¶µ¡¤Æî Ãҵס¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¢Æþß· Á±üÀî ³Ø¡¤ÌÚ²¼Íøɧ ; ǾÇÈ°Û¾ï¤òȼ¤Ã¤¿¼ãǯ¼þ´üÀº¿Àɤΰì¾ÉÎã¡¥Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï181)11-15
  14. Ë̸µ ·ò¡¤¹âÀ¥¾¡¶µ¡¤»³ÅÄ·½Â¤¡¤ÌÚ²¼Íøɧ ; ¿ÇÃǤ¬º¤Æñ¤Ç¤¢¤Ã¤¿Ê£»¨Éôʬȯºî¤Î£±¾ÉÎã¡¥Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï19(1)11-16
  15. ÎëÌÚÈþº´ ; Âç³Øɱ¡¤Ë¤ª¤±¤ëÀº¿ÀÊÝ·òÊ¡»ã»Î¤ÎÌò³ä.ÆüËÜÀº¿À²Êɱ¡¶¨²ñ»¨»ï28(9)738-743
  16. ¿ùËÜãºÈ¡¤´äÀ¥Àµ¸²¡¤µÜºê½¨¹Ô¡¤Æ£¸¶¹°²Â¡¤ÌÚ²¼Íøɧ¡¤ÃæëÔèÃË ; 2¥ö·î´Ö¥Õ¥©¥í¡¼¥¢¥Ã¥×¤·¤¿°ì»À²½ÃæÆǽ¸ÃÄȯÀ¸»öÎã¤ÎÊó¹ð¡¥»º¶È°å¥¸¥ã¡¼¥Ê¥ë31(1)18-22
  17. ÖÖË̲µ±¡¤µÈÅľ﹧¡¤À¾ÅÄ·½°ìϺ¡¤²Ï ÁêµÈ¡¤ºä°æ»ÖÈÁ¡¤Ê¬ÌîÀµµ®¡¤²ÃÆ£Àµ¼ù¡¤±üÀî ³Ø¡¤ÌÚ²¼Íøɧ ; ParoxetineÅêÍ¿¤Ë¤è¤êÁ°Æ¬Íվɾõ¤Î²þÁ±¤ò¤ß¤¿Á°Æ¬Â¦Æ¬ÊýǧÃξÉ(frontotemporal dementia)¤Î£±Îã¡¥Àº¿À²Ê13(2)165-172
  18. ÎëÌÚÊþ»Ò ; ¤¢¤«¤é¤µ¤Þ¤Ê¥¨¥Ç¥£¥×¥¹´ê˾¤ò¤á¤°¤ë¾ÉÎã¡¥Àº¿ÀʬÀϸ¦µæ52(1)84-89
  19. ÎëÌÚ½ÓÌÀ¡¤Ã«Ëü´î»Ò¡¤¼ã»³°éϺ¡¤µÈÅĽ¡Ê¿¡¤ÌÚ²¼Íøɧ¡¤ÌøÀ¸Î´»ë¡¢¹âÅĤ¢¤ä¡¤°æ¾åÇ ; ¥¸¥¹¥È¥Ë¥¢´µ¼Ô¤ËÂФ¹¤ë謁£ÎŸú²Ì¤Ë´Ø¤¹¤ë¸¡Æ¤ ¡Ý¶ÚÅÅ¿Þ³ØŪɾ²Á¤È¿´ÍýŪ¦Ì̤«¤é¤Îɾ²Á¡Ý¡¥´ØÀ¾°åÎÅÂç³ØµªÍ×£²:110-117
  20. µÈÌî¿¿µª¡¤ÃæÊ¿¶Ç»Ò¡¤¿¥ÅÄ͵¹Ô¡¤ÎëÌÚÊþ»Ò¡¤ÅĶá ʸ¡¤Í­Ìڱʻҡ¤ÌÚ²¼Íøɧ ; ¥í¡¼¥ë¥·¥ã¥Ã¥Ï¥Æ¥¹¥È¤«¤é¤ß¤¿À­Æ±°ìÀ­¾ã³²¡¥¿´ÍýÎ×¾²³Ø¸¦26(1)13-23
  21. ÃæÊ¿¶Ç»Ò¡¤µÈÌî¿¿µª¡¤¿¥ÅÄ͵¹Ô¡¤ÎëÌÚÊþ»Ò¡¤ÅĶá ʸ¡¤Í­Ìڱʻҡ¤ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²¤Ë¤ª¤±¤ë¥í¡¼¥ë¥·¥ã¥Ã¥Ï¥Æ¥¹¥È¤ÎÆÃħ¡ÝMTF¤ÈFTM¤ÎÈæ³Ó¤«¤é¡Ý¡¥¥í¡¼¥ë¥·¥ã¥Ã¥ÏË¡¸¦µæ12(1)1-9
  22. Ê¡ÅĹä»Ë¡¤»³²¼·Ã¼Â¡¤Åì ½ã°ì¡¤²ÃÆ£Àµ¼ù ; ¹³¤¦¤ÄÌô¤Î¼£ÎŸú²Ì¤Ë±Æ¶Á¤¹¤ëʬ»Ò¤Ë´Ø¤¹¤ë¥²¥Î¥àÌôÍý³ØŪ¸¦µæ¡ÝǾÆðÛŪtryptophan hydroxylase2¡Ý£²°äÅÁ»Ò·¿¤òÃæ¿´¤Ë¡¥Î×¾²ÌôÍý¤Î¿ÊÊâ29:155-167
  23. ²£¾®Ï©Èþµ®»Ò¡¤»°ÆÑ°¡ÈÞ¡¤Ä¹Èø´î°ìϺ¡¤ÌÚ²¼Íøɧ ; ¥ê¥¹¥Ñ¥À¡¼¥ë¤«¤é¥¸¥§¥Í¥ê¥Ã¥¯¤Î¥ê¥¹¥Ú¥ê¥É¥ó¤ËÊѹ¹¤·Àº¿À¾É¾õ¤¬°­²½¤·¤¿Åý¹ç¼ºÄ´¾É¤Î£±Îã¡¥ ¿·Ìô¤ÈÎ×¾²57(3):346-366
  24. ¼ºê¸÷Ë®¡¤¾®»³ »Ê¡¤°ËЮ²í¿Ã¡¤Àж¿²¬½ã¡¤¾åÅç¹ñÍø¡¤È¬ÌÚ¹äÊ¿¡¤ÈøºêµªÉס¤Ê¡µï¸²Æó¡¤ÉðÅIJí½Ó¡¤ÊÆÅÄ ÇÌÚ²¼Íøɧ¡¤¿ÀÄí½Å¿®¡¤Á°Åĵ×ͺ Perospirone¤Î½éȯÅý¹ç¼ºÄ´¾É¤ËÂФ¹¤ë»ÔÈθåÄ´ºº ¡ÝÍ­¸úÀ­¤È°ÂÁ´À­¤Î¸¡Æ¤¡½¡¥Î×¾²Àº¿ÀÌôÍý11(8)1531-1550

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ÌÚ²¼Íøɧ ; ¡ÚÅý¹ç¼ºÄ´¾É¤ÎÌôʪÎÅË¡ ¥Ö¥í¥Ê¥ó¥»¥ê¥ó¤Îup to date¡Û¥Ö¥í¥Ê¥ó¥»¥ê¥ó¤Î´ðÁäÈÎ×¾²¡¥Àº¿À²Ê13(6)457-465
  2. ÌÚ²¼Íøɧ ; ¥á¥é¥ó¥³¥ê¥¢¡¥ºÇ¿·Àº¿À°å³Ø13(5)411
  3. ÌÚ²¼Íøɧ¡¤À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë ; Ìôʪ¤ª¤è¤Ó¼£ÎŤαƶÁ¡¥Î×¾²¿À·ÐÀ¸Íý³Ø²ñ 36(1-2):56-62
  4. ¿¥ÅÄ͵¹Ô¡¤ÀÐÀîͳÈþ»Ò¡¤¿ÀÀè ¿¿¡¤¿ùËÜãºÈ¡¤À± ¹î¿Î¡¤´Ø¹çÀ¬»Ò¡¤Æî ÎÉÉð ; ¥Á¡¼¥à°åÎŤθ½¾ì¤«¤é¡Ö´ä¼ê¸©µ×»üÃÏ°è¤Ë³Ø¤Ö¼«»¦Í½ËÉÂкö¡×¡¥¤³¤³¤í¤ò»Ù¤¨¤ë3(3)3-7
  5. ±üÀî ³Ø¡¤²ÃÆ£Àµ¼ù¡¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ¥ª¡¼¥À¡¼¥á¥¤¥ÉÀº¿À²ÊÌôʪÎÅË¡¤ò¤á¤¶¤·¤Æ ¤¦¤ÄɤÎÌôʪÎÅË¡¤Ë¤ª¤±¤ë¥ª¡¼¥À¡¼¥á¥¤¥É°åÎÅ¡¥Àº¿À¿À·Ð³Ø»¨»ï110(8)623-627
  6. ±üÀî ³Ø¡¤²ÃÆ£Àµ¼ù¡¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ¾­Íè¡¢´üÂÔ¤µ¤ì¤ë¹³¤¦¤ÄÌô¤Î¸¦µæ¤È³«È¯¡¥ºÇ¿·Àº¿À°å³Ø13(5)457-462
  7. ¿ùËÜãºÈ ; ¤³¤ó¤Ê¾ì¹ç¤Ï¤É¤¦¤¹¤ë¡Ö¼«»¦¤Ë¤ª¤±¤ëµßµÞ°åΟ½¾ì¤ÈÀº¿À²Ê°åΟ½¾ì¤ÎÏ¢·È¡×¡¥¤³¤³¤í¤ò»Ù¤¨¤ë3(3)18-20
  8. ¿ùËÜãºÈ ; µßÌ¿¥»¥ó¥¿¡¼¤Ë¾ïÃ󤹤ëÀº¿À²Ê°å¤¬Æ¯¤¯¤È¤¤¤¦¤³¤È¡¥Àº¿À²Êɱ¡¥Þ¥Í¥¸¥á¥ó¥È9:7
  9. ÖÖË̲µ±¡¤À¾ÅÄ·½°ìϺ¡¤ÌÚ²¼Íøɧ ; Æý¸¡Ý³Æ¼ïÌôʪ¤Î½èÊý¤ÈÃí°ÕÅÀ Àº¿À²ÊÎΰè¡Ý¹³¤Æ¤ó¤«¤óÌô¡¥
    °å³Ø¤ÈÌô³Ø ; 60(2)186-194
  10. ¾åÌîÀéÊ桤ÌÚ²¼Íøɧ(2008Æý¸¤Ë¤¢¤¿¤Ã¤Æ¡¥ºÇ¿·Àº¿À°å³Ø13(3)223-225
  11. ʬÌîÀµµ®¡¤²ÃÆ£Àµ¼ù¡¤ÖÖË̲µ±¡¤ºä°æ»ÖÈÁ¡¤À¾ÅÄ·½°ìϺ¡¤±üÀî ³Ø¡¢ÌÚ²¼Íøɧ ; Æý¸ ¹³¤¦¤ÄÌô ¥Ñ¥í¥­¥»¥Á¥ó(¥Ñ¥­¥·¥ë)¡¥ºÇ¿·Àº¿À°å³Ø13(5)435-438
  12. µÈ¼¶©»Ë¡¤À¾ÅÄ·½°ìϺ¡¤¿¹ÅļÓÀ顤ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ¡ÚÀº¿À¼À´µ¤ÎÎ×¾²¿À·ÐÀ¸Íý³ØŪ¸¦µæ¤ÎºÇ¿·Ãθ«¡Û ÌôʪÎÅË¡¤ÎÎ×¾²¿À·ÐÀ¸Íý³ØŪ¸¦µæ¡¥Î×¾²Àº¿À°å³Ø37(10)1335-1343
  13. °ëë½ÓÌÀ¡¤ ¿¹ÅļÓÀ顤À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë¡¤Æþß· ÁºØÆ£¼ë¼Â¡¤ ÌÚ²¼Íøɧ ; ·ò¾ï¼Ô¤Ë¤ª¤±¤ëaripiprazole¤ÎǾÇȤؤαƶÁ¡¥Î×¾²¿À·ÐÀ¸Íý³Ø36(5)598
  14. À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë¡¤µÈÅľ﹧¡¤ Æþß· Á°ëë½ÓÌÀ¡¤Ë̱ºÍ´°ì¡¤ÌÚ²¼Íøɧ ; FTD(frontotemporal dementia)´µ¼Ô¤ÎǾÇȼþÇÈ¿ôÄêÎ̲òÀÏ¡¥Î×¾²¿À·ÐÀ¸Íý³Ø36(5)598
  15. ÌÚ²¼Íøɧ ; ǾÇÈÇÈ·Á¤ÎÀµ¾ï¤È°Û¾ï¡¥Î×¾²¿À·ÐÀ¸Íý³Ø36(5)503
  16. °¤Éô¾°¡¤ÅĶᰡÍö¡¤ºä°æ»ÖÈÁ¡¤Ê¬ÌîÀµµ®¡¤¾åÌîÀéÊ桤ÌÚ²¼Íøɧ ; ¥¨¥È¥µ¥¯¥·¥ß¥É¤Ë¤è¤ëǾÇȤζ¯À©Àµ¾ï²½¤«¤é̵¸À¡¦²ÉÆ°¤òÄ褷¤¿°ìÎã¡¥Àº¿À¿À·Ð³Ø»¨»ï110(10)987
  17. »°°æ ¹À¡¤Ã« Ëü´î»Ò, ÌøÀ¸Î´»ë¡¤¹âÅĤ¢¤ä¡¤À¾Â¼±ÉÄŻҡ¤²¬Â¼¹¨Èþ, µÈÌî¿¿µª¡¤ÎëÌÚÊþ»Ò¡¤ÎëÌÚ½ÓÌÀ¡¤ÌÚ²¼Íøɧ ; ´ØÀ¾°å²ÊÂç³ØÀº¿À¿À·Ð²Ê¤Ë¤ª¤±¤ë¥¸¥¹¥È¥Ë¥¢¼£ÎŤλî¤ß¡¥Àº¿À¿À·Ð³Ø»¨»ï ; ÆÃÊÌ PageS-214
  18. ÎëÌÚ Ê⡤ÊÒ¾åůÌ顤Ë̸µ ·ò¡¤»°°æ ¹À¡¤¿¥ÅÄ͵¹Ô¡¤ ÌÚ²¼Íøɧ ; ¿ÇÃǤËÆñ½Â¤·¤¿Åý¹ç¼ºÄ´¾É¤Î1Îã¡¥Àº¿À¿À·Ð³Ø»¨»ï110(10)981
  19. ÎëÌÚÊþ»ÒÇϾ츬°ì, ¾¾Ëܵþ²ð) ; ³Ø¹»¤Ë¤ª¤±¤ë¿´Íý¸¡ºº(Âè2Éô¥¹¥¯¡¼¥ë¥«¥¦¥ó¥»¥ê¥ó¥°¤Î¼ÂºÝ Âè4¾ÏÊݸî¼Ô¤È¤Î¤«¤«¤ï¤ê)¡¥¥¹¥¯¡¼¥ë¥«¥¦¥ó¥»¥ê¥ó¥°¤Î´ðÁäȷи³ ; 77-86
  20. ÛȾìÈþÊ桤ÎëÌÚÊþ»Ò¡¤ÊÒ¾åůÌ顤 ÅĶᰡÍö¡¤ÌÚ²¼Íøɧ ; ¥¹¥¯¡¼¥ë¡¦¥«¥¦¥ó¥»¥é¡¼¤Î¥³¥ó¥µ¥ë¥Æ¡¼¥·¥ç¥ó³èÆ° »×½Õ´ü¤ÎÌäÂê¹ÔÆ°¤Ø¤ÎÂбþ Àº¿À¿À·Ð³Ø»¨»ï110(10986
  21. ¹âÅĤ¢¤ä¡¤ÌøÀ¸Î´»ë¡¤Ã« Ëü´î»Ò¡¤»°°æ ¹À¡¤À¾Â¼±ÉÄŻҡ¤²¬Â¼¹¨Èþ, µÈÌî¿¿µª¡¤ÎëÌÚÊþ»Ò¡¤ÎëÌÚ½ÓÌÀ¡¤ ĹÈø´î°ìϺ¡¤ÌÚ²¼Íøɧ ; MMPI(¥ß¥Í¥½¥¿Â¿Ì̿ͳÊÌÜÏ¿)¤òÍѤ¤¤¿ÆÃȯÀ­¥¸¥¹¥È¥Ë¥¢´µ¼Ô¤Î¿´ÍýÆÃÀ­¤Î¸¡Æ¤¡¥Àº¿À¿À·Ð³Ø»¨»ï ; ÆÃÊÌ S-214
  22. Ãæ¹þϹ¬¡¤µíÅçÄê¿®¡¤ÂçÄÚÅ·Ê¿¡¤ÌÚ²¼Íøɧ¡¤µ×ÊÝÌÚÉÙ˼¡¤µ×ÊÝÀé½Õ¡¤±ÛÌʸ¡¤¾®»³ »Ê¡¤ÅÄÅç ¼£¡¤Ãæ°æµÈ±Ñ¡¤Ãæ¼ ½ã¡¤Ã°±©¿¿°ì¡¤Ìî¼Áí°ìϺ¡¤Èõ¸ýµ±É§¡¤Â¼ºê¸÷Ë®¡¤¾åÅç¹ñÍø ; GAD¸¦µæ²ñ¤¬Ä󾧤¹¤ëËÜË®¤Ë¤ª¤±¤ë¡ÖGAD¼£Îżê½ç¡×¡¥Î×¾²Àº¿ÀÌôÍý11(8)1571-1573
  23. Ãæ¹þϹ¬¡¤µíÅçÄê¿®¡¤ÂçÄÚÅ·Ê¿¡¤ÌÚ²¼Íøɧ¡¤µ×ÊÝÌÚÉÙ˼¡¤µ×ÊÝÀé½Õ¡¤±ÛÌʸ¡¤¾®»³ »Ê¡¤ÅÄÅç ¼£¡¤Ãæ°æµÈ±Ñ¡¤Ãæ¼ ½ã¡¤Ã°±©¿¿°ì¡¤Ìî¼Áí°ìϺ¡¢Èõ¸ýµ±É§¡¤Â¼ºê¸÷Ë®¡¤¾åÅç¹ñÍø ; ¤ï¤¬¹ñ¤Î¼ÂÂ֤˴ð¤Å¤¤¤¿GAD¼£Îżê½ç¡¥Î× ¾²Àº¿ÀÌôÍý11(9)1786-1791
  24. À¾»³ÍøÀµ¡¤»°Åç¿­²ð¡¤ÀÐÅĹâÌÀ¡¤ÅĶᰡÍöÈøÆâ°ì¿®) ; Ãæ¹ñºßαˮ¿Í¤Ë¤ª¤±¤ë¥È¥é¥Ù¥ë¥ï¥¯¥Á¥ó¼Â»Ü¾õ¶·¡Ý¾å³¤»ÔÆâ¤Î¾õ¶·¡Ý¡¥¸üÀ¸Ï«Æ¯²Ê³Ø¸¦µæÈñÊä½õ¶â,¿·¶½¡¦ºÆ¶½´¶À÷¾É¸¦µæ»ö¶È. ³¤³°ÅϹҼԤËÂФ¹¤ëͽËÉÀܼï¤Î¤¢¤êÊý¤Ë´Ø¤¹¤ë¸¦µæÊ¿À®19ǯÅÙ Áí³ç¡¦Ê¬Ã´¸¦µæÊó¹ð½ñ72-78
  25. À¾»³ÍøÀµ¡¤»°Åç¿­²ð¡¤ÀÐÅĹâÌÀ¡¤ÅĶᰡÍöÈøÆâ°ì¿®) ; ºßαˮ¿Í¤Î¥È¥é¥Ù¥ë¥ï¥¯¥Á¥ó¼Â»Ü¾õ¶·¤Ë´Ø¤¹¤ë¸¦µæ(Ãæ²Ú¿Í̱¶¦Ï¹ñ¤ËÃíÌܤ·¤Æ)¡¥ ¸üÀ¸Ï«Æ¯²Ê³Ø¸¦µæÈñÊä½õ¶â,¿·¶½¡¦ºÆ¶½´¶À÷¾É¸¦µæ»ö¶È. ³¤³°ÅϹҼԤËÂФ¹¤ëͽËÉÀܼï¤Î¤¢¤êÊý¤Ë´Ø¤¹¤ë¸¦µæÊ¿À®17ǯÅÙ¡Á19ǯÅÙ Áí¹çô¸¦µæÊó¹ð½ñ81-102

Ãø½ñ

  1. ÌÚ²¼Íøɧ ; ¤¦¤Äɤò»ý¤Ä¿Í¤Î¿´¤ÎÍÍÁê¡¥¿·¸½Âå¤Î¥¨¥¹¥×¥êNo.487 ³°ÍèÀº¿À°åÎÅ¥·¥ê¡¼¥º­¶ ¸½Âå¤Î¤³¤³¤í¤ÎÉ pp47-56 »êʸƲ
  2. µÈÌî¿¿µª¡¤ÃæÊ¿¶Ç»Ò ; ¿´ÍýÎ×¾²¤ÈÅê±ÆË¡ ¥¸¥§¥ó¥À¡¼ÌäÂê¤ÈÅê±ÆË¡¡¥ ¸½Âå¤Î¥¨¥¹¥×¥ê(Ê̺ý10·î)236-244

¥Ú¡¼¥¸TOP¤ØÌá¤ë